Revvity Launches pHSense Reagents to Revolutionize Internalization Studies in Drug Discovery

Published: 08 Aug 2025

Author: Precedence Research

Share :

Revvity, Inc. has launched its newest innovation in drug discovery tools, pHsense reagents, an improved next-generation technology to provide higher accuracy and efficiency in internalization studies. Designed to address modern-day high-throughput drug screening bioassays, the pHSense reagents present an efficient and easy-to-use option to scientists working on G protein-coupled receptors (GPCRs), antibody-drug conjugates (ADCs), and other therapies involving internalization as an action and optimizing a new dye chemistry with a pH response and using time-resolved fluorescence (TRF) as the readout. The pHSense reagents provide an exquisitely sensitive detection platform to generate reproducible internalization kinetics, even with low receptor expression levels.

The system is also compatible with any traditional plate readers and can be integrated into current systems without interfering with existing systems. This offers flexibility to the researchers who can readily integrate this solution within their laboratory infrastructure. The high signal-to-background ratio and the reproducible kinetic data make the pHSense a unique tool that drives the acceleration of drug discovery procedures and reduces the cost of the process. Drug discovery is becoming more complex, and the industry is leveraging biologics, targeted therapies, and precision medicine. The need to utilize tools able to research receptor dynamics with accurate precision has increased exponentially.

The importance of internalization studies, particularly of ADCs and GPCR-targeting drugs, is that they help to understand the therapeutic effects of the drug once it binds to a target cell receptor. Nevertheless, most available technologies to monitor these mechanisms lack throughput, reproducibility, or sensitivity, especially in low-expression systems.

Another strategic decision in the launch of pHSense is that it is in line with the trends in drug discovery queries, such as the development of antibody-drug conjugates and the revival of GPCRs as a serviceable drug target. As ADCs gain popularity in the field of oncology, it is notable that the effectiveness of payload delivery is hinged on the ability to monitor internalizing behaviour. Toward this end, it is vital to possess how this can be achieved. Likewise, with GPCR biology increasingly coupled with immune modulation and neurobiology, accurate and scalable technologies such as pHSense will play a non-negotiable role in next-generation drug development.